Ergotamine in the acute treatment of migraine: A review and European consensus | Zendy

Peer TfeltHansen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ergotamine in the acute treatment of migraine: A review and European consensus

Author(s) -

Peer TfeltHansen

Publication year - 2000

Publication title -

brain

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.142

H-Index - 336

eISSN - 1460-2156

pISSN - 0006-8950

DOI - 10.1093/brain/123.1.9

Subject(s) - ergotamine , migraine , headaches , medicine , sumatriptan , dosing , clinical practice , intensive care medicine , migraine treatment , acute migraine , anesthesia , alternative medicine , psychiatry , physical therapy , pharmacology , placebo , receptor , pathology , agonist

Ergotamine has been used in clinical practice for the acute treatment of migraine for over 50 years, but there has been little agreement on its place in clinical practice. An expert group from Europe reviewed the pre-clinical and clinical data on ergotamine as it relates to the treatment of migraine. From this review, specific suggestions for the patient groups and appropriate use of ergotamine have been agreed. In essence, ergotamine, from a medical perspective, is the drug of choice in a limited number of migraine sufferers who have infrequent or long duration headaches and are likely to comply with dosing restrictions. For most migraine sufferers requiring a specific anti-migraine treatment, a triptan is generally a better option from both an efficacy and side-effect perspective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research